#Class Action #Pomerantz #RxSight

Investor Alert: Pomerantz Law Firm Takes Action Against RxSight, Inc.

The Pomerantz Law Firm is urging investors who have suffered losses from their investment in RxSight, Inc. to be aware of a class action lawsuit that has been initiated against the company. Investors who purchased or otherwise acquired securities of RxSight (NASDAQ: RXST) during the class period are encouraged to act before the deadline of September 22, 2025. To initiate claims, interested parties can reach out to Danielle Peyton at Pomerantz via email or phone to secure their position in the case.

The allegations within the class action are serious, claiming that RxSight and its executives may have engaged in securities fraud and other illicit business practices. This lawsuit appears particularly relevant given the company's recent financial disclosures, which showcased a troubling pattern in sales performance and utilization metrics.

On July 8, 2025, RxSight disclosed its preliminary financial results for the second quarter, signaling a major downturn with a substantial drop in sales of its Light Delivery Devices (LDD), alongside a decrease in the adoption of its light adjustable intraocular lenses. Furthermore, the company issued guidance for the remainder of 2025, slashing projections by an estimated $42.5 million, highlighting the challenges that have hit the company over the last few quarters. CEO Ronald Kurtz articulated that these